BioAscent Discovery

Newhouse, Scotland, UK
GPCR drug discovery GPCR assay development and screening Medicinal chemistry In-silico/computational chemistry Integrated drug discovery
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (1) ○ EMA GMP ○ MHRA GMP

Quick Facts: BioAscent Discovery

Signal Score
60.0/100
Quality Compliance
Assessment pending
Headquarters
Newhouse, Scotland, UK
Modalities
GPCR drug discovery, GPCR assay development and screening, Medicinal chemistry, In-silico/computational chemistry, Integrated drug discovery
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About BioAscent Discovery

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesGPCR drug discovery, GPCR assay development and screening, Medicinal chemistry, In-silico/computational chemistry, Integrated drug discovery
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
Broad modality coverage (5 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press1 articles
Broad modality coverage (5 modalities)

Recent News 1 articles

news Wed, 01 No
Drug Discovery Services Market Report 2025-2030, By Process, Type, and Geo - MarketsandMarkets
Source →

Frequently Asked Questions About BioAscent Discovery

What is BioAscent Discovery's CDMO Signal Score?
BioAscent Discovery has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating BioAscent Discovery for a manufacturing program?
Use the free AI matchmaker to compare BioAscent Discovery against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.